Intellia Therapeutics (NTLA) Total Liabilities (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Total Liabilities of $137.8 million for Q1 2026, down 33.17% year-over-year from $206.2 million in Q1 2025, and down 19.27% quarter-over-quarter from $170.7 million in Q4 2025.
Intellia Therapeutics (NTLA) Total Liabilities (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Total Liabilities for 12 consecutive years, with $137.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 33.17% year-over-year to $137.8 million; the TTM figure through Mar 2026 stood at $137.8 million (down 33.17% YoY), while the FY2025 annual figure was $170.7 million, down 46.49% from the prior year.
- Total Liabilities fell to $137.8 million in Q1 2026 per NTLA's latest filing, from $170.7 million in the prior quarter.
- Across five years, Total Liabilities topped out at $1.4 billion in Q1 2023 and bottomed at $137.8 million in Q1 2026.
- Historically, Total Liabilities has averaged $513.5 million across 5 years, with a median of $223.5 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 67.78% — and 2024, when it sank 84.24%.
- Intellia Therapeutics' Total Liabilities stood at $284.5 million in 2022, then decreased by 11.85% to $250.8 million in 2023, then grew by 27.21% to $319.1 million in 2024, then plunged by 46.49% to $170.7 million in 2025, then fell by 19.27% to $137.8 million in 2026.
- Business Quant data shows NTLA's Total Liabilities at $137.8 million in Q1 2026, $170.7 million in Q4 2025, and $176.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 129.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 129.46 Mn |
| Mar 31, 2026 | 137.84 Mn |
| Dec 31, 2025 | 170.73 Mn |
| Sep 30, 2025 | 176.85 Mn |
| Jun 30, 2025 | 183.64 Mn |
| Mar 31, 2025 | 206.24 Mn |
| Dec 31, 2024 | 319.06 Mn |
| Sep 30, 2024 | 210.74 Mn |
| Jun 30, 2024 | 220.47 Mn |
| Mar 31, 2024 | 223.45 Mn |
| Dec 31, 2023 | 250.81 Mn |
| Sep 30, 2023 | 205.94 Mn |
| Jun 30, 2023 | 1.32 Bn |
| Mar 31, 2023 | 1.42 Bn |
| Dec 31, 2022 | 284.53 Mn |
| Sep 30, 2022 | 1.08 Bn |
| Jun 30, 2022 | 1.11 Bn |
| Mar 31, 2022 | 1.20 Bn |
| Dec 31, 2021 | 1.29 Bn |
| Sep 30, 2021 | 1.33 Bn |